CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
OKLAHOMA CITY, March 14, 2017 -- Cytovance® Biologics, a leading CDMO who provides unparalleled support to biopharmaceutical companies to move candidate molecules from the bench to commercial manufacturing, announces today that it has received a CMO Leadership Award in three categories; Quality, Reliability and Compatibility, which will be given at the CMO Leadership Awards Ceremony to be held March 22, 2017, at the W Hotel in New York City, NY.
“Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Executive Editor, Life Science Leader magazine and OutsourcedPharma.com. “Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the 6 critical categories of capabilities, compatibility, expertise, quality, reliability and development. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”
“We are honored to be awarded as a leader in the categories of Quality, Reliability and Compatibility by our clients in the CDMO marketplace,” stated Darren Head, President and CEO of Cytovance. “Cytovance Biologics proudly employs a highly experienced team, and we remain ever-cognizant of the significance of providing unparalleled service to our clients. We accept this award as a testament of the dedication and hard work of many within our remarkable company."
About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Contact: Cheryl Soerensen [email protected] 405.319.8310
